Le Lézard
Classified in: Health
Subject: VET

U.S. House Bill to Address Compensation for Veterans, Families Toxic Exposure at Nevada Nuclear Test Site


LAS VEGAS, April 11, 2023 /PRNewswire/ -- A Bill is being drafted in the U.S. House of Representatives to provide compensation and restitution for U.S. Military personnel and their families who have suffered from exposure to radiation and toxic materials as a result of nuclear testing at the Tonopah Test Range.

US Rep. Mark Amodei, (R-Nev.), will introduce the Bill in response to research by US Air Force Veteran David Crete.

U.S. Congressman Mark Amodei, (R-Nev.), serving the 2nd District of Nevada, will introduce the Bill in response to research and reports by U.S. Air Force veteran David Crete.

From 1983 to 1987, Crete was a member of the 4461st Security Police Squadron based at the highly classified Tonopah Test Range (TTR) in remote Nevada. The unit provided operational security for America's top-secret F-117A stealth aircraft. Three other Air Force units and additional Department of Defense (DoD) personnel were also stationed at TTR during this time.

They did not know the Department of Energy (DoE) and Sandia National Laboratories had conducted nuclear testing at TTR decades before they arrived. They also didn't know TTR's soil and water were contaminated with ionizing radiation from Plutonium 239 and other highly toxic materials. The bill alleges no measures were taken to protect the military or civilian personnel at TTR from these dangerous substances.

Crete has documented the effects of the exposure to these contaminants on his fellow servicemen and their families. Many are suffering from various cancers, cardiovascular disease, pulmonary disease and other serious health issues. Many have died. Many women have experienced miscarriages and many of their children have been born with birth defects.

Weapons testing and other activities at TTR and other highly contaminated sites throughout the Nevada Test and Training Range (NTTR) continue to this day.

In 2000, President Bill Clinton signed Executive Order 13179, which, in part, read: "While the Nation can never fully repay these workers or their families, they deserve recognition and compensation for their sacrifices. Since the Administration's historic announcement in July 1999 that it intended to compensate DOE nuclear weapons workers who suffered occupational illnesses as a result of exposure to the unique hazards in building the Nation's nuclear defense, it has been the policy of this Administration to support fair and timely compensation for these workers and their survivors."

This order applied only to DoE and other civilian workers. To date, more than $23 billion in compensation and medical expenses have been paid. DoD personnel, including the Air Force units that served throughout NTTR/TTR and their families, were not eligible to receive fair and timely compensation for their sacrifices.

After 30 years, the pending House Bill seeks to rectify this injustice.

A .pdf presentation by Dave Crete is available at: https://www.dropbox.com/s/2gdm8j8e91iz2cj/The%20Invisible%20Enemy%20at%20TTR_2023.pdf?dl=0

Dave Crete is available for interviews. To schedule an interview contact:

Virginia Martino, Brand LTD (702) 591-9183 [email protected] or

Richard Gubbe, Brand LTD (815) 670-2620 [email protected]

SOURCE U.S. Air Force Veteran David Crete


These press releases may also interest you

at 05:05
Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced the appointment of Dale Levitzke as CEO with immediate effect, as Dr. Frank F. Craig, current CEO and co-founder,...

at 05:05
Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb's drug...

at 05:00
As PetSafe® continues to lead the way in pet-tech innovations, we are proud to introduce the next evolution in pet fountains: the PetSafe® Outlasttm 90 oz Pumpless Pet Fountain with patented HydroSpintm technology....

at 05:00
BioMed X, a German biomedical research institute, announces the start of a new research project in partnership with Merck at its site in Heidelberg, Germany. The main objective of the project is to develop novel immunotherapeutic strategies to...

at 04:52
Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled,...

at 04:09
A news report from China Daily: The 2024 ZGC Forum in Beijing showcased a wide range of latest technological innovations. The event ran from April 25 to 29 and comprised 128 activities, including forums and conferences, technology exchanges,...



News published on and distributed by: